FDA OKs ANI Pharma dementia med

The FDA approves ANI Pharmaceuticals’ (ANIP -5.1%) Memantine Hydrochloride Extended-Release Capsules 7 mg, 14 mg, 21 mg and 28 mg, a generic version of Teva Pharmaceutical Industries’ (TEVA) Namenda XR, approved in the U.S. in June 2010 for Alzheimer’s disease-related dementia (Forest Laboratories).

Per IQVIA, the U.S. market is ~$127M.

https://seekingalpha.com/news/3547533-fda-oks-ani-pharma-dementia-med